Sep 04, 2020
The Keratoconus market will be dominated by lenses, cross-linking procedures as well as IVMED-80, if approved in the coming decade. Keratoconus, away from the general perception of a rare disease, has come a long way. Thirty-four years back, in Minnesota, United States, this disease was claimed as rare, which cr...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper